GlassScriptPhysician profile
Rachel Koppenol
NPI 1972191575
$3,605.77
in general payments reported to CMS, 2019-2025
13 companies · $1,379 in 2025
The $1,379 reported for 2025 was more than what 88% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $628 · 2023: $1,044 · 2024: $555 · 2025: $1,379.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,876 · Education: $101.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,875.96 |
| Education | $101.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $895.03 | 2022-2025 | Nucala |
| Regeneron Healthcare Solutions, INC. | $639.83 | 2022-2025 | Dupixent |
| Genzyme Corporation | $472.62 | 2023-2025 | |
| Medtronic, INC. | $456.97 | 2024-2025 | Ligasure, Sinuva, Stealthstation S8 Platform |
| Astrazeneca Pharmaceuticals LP | $249.98 | 2022 | |
| Optinose US, INC. | $244.92 | 2023 | |
| Stryker Corporation | $153.14 | 2025 | Scopis Ent |
| Hologic Sales and Service, LLC | $133.97 | 2024 | Coolseal Generator |
| Acclarent, INC | $133.00 | 2024 | Trudi Nav Cable, Relieva Tract |
| Neurent Medical Limited | $120.35 | 2023 | Neuromark Device, Neuromark Radiofrequency Console |
| Phadia US INC. | $58.61 | 2023 | Immunocap |
| Novartis Pharmaceuticals Corporation | $26.34 | 2025 | |
| Ars Pharmaceuticals Operations, INC. | $21.01 | 2025 | Neffy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rachel Koppenol listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.